GLS Pharma Ltd

Pemetrexed is among the promising discoveries of the 21st century that changed treatment paradigm for a sub-population of lung cancer patients.

Pemetrexed is among the promising discoveries of the 21st century that changed treatment paradigm for a sub-population of lung cancer patients.Pemetrexed is a multitargeted antifolate that inhibits atleast three folate dependant enzymes involved in DNA synthesis. It is the first choice chemotherapeutic drug for  advanced or metastatic non-small cell lung cancer (NSCLC) patients with nonsquamous histology.

Indications:

• For the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer in combination with cisplatin therapy

• For the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy

• For the treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer as a single-agent after prior chemotherapy

• For the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery in combination with cisplatin